Kotoko Yamatani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kotoko Yamatani has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Yoko Tabe
Department of Clinical Laboratory Medicine Juntendo University Graduate School of Medicine Tokyo Japan
3 shared publications Haeun Yang
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
2 shared publicationsKaori Saito
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
2 shared publications- Marina Konopleva
Albert Einstein College of Medicine
2 shared publications - Michael Andreeff
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2 shared publications - Takashi Miida
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (Sagara, Hirayama, Fukushima, Ueno, and Miida); Department of Clinical Laboratory Science, Juntendo University Graduate School of Medical Science, Urayasu, Japan (Miida)
2 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 178
Ex vivo γ-globulin treatment of oocytes in women with anticentromere antibody–related infertility: An exploratory phase I/II study
- 20 October 2026
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 178
Open AccessEx vivo γ-globulin treatment of oocytes in women with anticentromere antibody–related infertility: An exploratory phase I/II study
- Open Access
- 19 May 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (3) , 100121
PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML
- 19 May 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (3) , 100121
Open AccessPPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML
- Open Access
- 25 October 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (20) , 4233-4255
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition
Acute myeloid leukemia (AML) cells are highly dependent on oxidative phosphorylation (OxPhos) for survival, and they continually adapt to fluctuations in nutrient and oxygen availability in the bone marrow (BM) microenvironment. We investigated how the BM microenvironment affects the response to OxPhos inhibition in AML by using a novel complex I OxPhos inhibitor, IACS-010759. Cellular adhesion, growth, and apoptosis assays, along with measurements of expression of mitochondrial DNA and generation of mitochondrial reactive oxygen species indicated that direct interactions with BM stromal cells triggered compensatory activation of mitochondrial respiration and resistance to OxPhos inhibition in AML cells. Mechanistically, inhibition of OxPhos induced transfer of mitochondria derived from mesenchymal stem cells (MSCs) to AML cells via tunneling nanotubes under direct-contact coculture conditions. Inhibition of OxPhos also induced mitochondrial fission and increased functional mitochondria and mitophagy in AML cells. Mitochondrial fission is known to enhance cell migration, so we used electron microscopy to observe mitochondrial transport to the leading edge of protrusions of AML cells migrating toward MSCs. We further demonstrated that cytarabine, a commonly used antileukemia agent, increased mitochondrial transfer of MSCs to AML cells triggered by OxPhos inhibition. Our findings indicate an important role of exogenous mitochondrial trafficking from BM stromal cells to AML cells as well as endogenous mitochondrial fission and mitophagy in the compensatory adaptation of leukemia cells to energetic stress in the BM microenvironment.
- 25 October 2021
- Published by American Society of Hematology in Blood Advances
- Vol. 5 (20) , 4233-4255
Open AccessExogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition
Acute myeloid leukemia (AML) cells are highly dependent on oxidative phosphorylation (OxPhos) for survival, and they continually adapt to fluctuations in nutrient and oxygen availability in the bone marrow (BM) microenvironment. We investigated how the BM microenvironment affects the response to OxPhos inhibition in AML by using a novel complex I OxPhos inhibitor, IACS-010759. Cellular adhesion, growth, and apoptosis assays, along with measurements of expression of mitochondrial DNA and generation of mitochondrial reactive oxygen species indicated that direct interactions with BM stromal cells triggered compensatory activation of mitochondrial respiration and resistance to OxPhos inhibition in AML cells. Mechanistically, inhibition of OxPhos induced transfer of mitochondria derived from mesenchymal stem cells (MSCs) to AML cells via tunneling nanotubes under direct-contact coculture conditions. Inhibition of OxPhos also induced mitochondrial fission and increased functional mitochondria and mitophagy in AML cells. Mitochondrial fission is known to enhance cell migration, so we used electron microscopy to observe mitochondrial transport to the leading edge of protrusions of AML cells migrating toward MSCs. We further demonstrated that cytarabine, a commonly used antileukemia agent, increased mitochondrial transfer of MSCs to AML cells triggered by OxPhos inhibition. Our findings indicate an important role of exogenous mitochondrial trafficking from BM stromal cells to AML cells as well as endogenous mitochondrial fission and mitophagy in the compensatory adaptation of leukemia cells to energetic stress in the BM microenvironment.
- 29 April 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 41 (6) , e134-e138
Performance evaluation of the Sysmex DI‐60 overview application for tumor cell detection in body fluid samples
- 29 April 2019
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 41 (6) , e134-e138
Performance evaluation of the Sysmex DI‐60 overview application for tumor cell detection in body fluid samples